Geçgel, A.; Şahin Çelik, B.; Peker, P.; Gökdere, Z.S.; Koca, D.; Karaca, B.; Nart, D.; Göker, E.
KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort. J. Clin. Med. 2025, 14, 6826.
https://doi.org/10.3390/jcm14196826
AMA Style
Geçgel A, Şahin Çelik B, Peker P, Gökdere ZS, Koca D, Karaca B, Nart D, Göker E.
KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort. Journal of Clinical Medicine. 2025; 14(19):6826.
https://doi.org/10.3390/jcm14196826
Chicago/Turabian Style
Geçgel, Aslı, Buket Şahin Çelik, Pınar Peker, Zeynep Sıla Gökdere, Didem Koca, Burçak Karaca, Deniz Nart, and Erdem Göker.
2025. "KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort" Journal of Clinical Medicine 14, no. 19: 6826.
https://doi.org/10.3390/jcm14196826
APA Style
Geçgel, A., Şahin Çelik, B., Peker, P., Gökdere, Z. S., Koca, D., Karaca, B., Nart, D., & Göker, E.
(2025). KRAS G12C Mutation Predicts Improved Survival in NSCLC Patients Receiving Immunotherapy: Insights from a Real-World Cohort. Journal of Clinical Medicine, 14(19), 6826.
https://doi.org/10.3390/jcm14196826